A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy
Keywords
Abstract
Description
About 60 gynecologic cancer patients' medical records are expected to collect and analyze in this retrospective study. The data collection from medical records of gynecologic cancer patients who had received chemotherapy with or without prescription drug treatment for cancer-related fatigue include the demographic information (e.g., height, weight, age, sex, tumor stage, time from tumor diagnoses, prescription drug of cancer-related fatigue treatment and chemotherapy toxicities), the diagnosis and severity of cancer-related fatigue, functional assessment of cancer therapy and so on.
Dates
Last Verified: | 01/31/2018 |
First Submitted: | 03/19/2017 |
Estimated Enrollment Submitted: | 03/19/2017 |
First Posted: | 03/23/2017 |
Last Update Submitted: | 02/10/2018 |
Last Update Posted: | 02/12/2018 |
Actual Study Start Date: | 10/18/2016 |
Estimated Primary Completion Date: | 12/30/2018 |
Estimated Study Completion Date: | 12/30/2018 |
Condition or disease
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Gynecologic cancer patients Gynecologic cancer patients under chemotherapy |
Eligibility Criteria
Ages Eligible for Study | 20 Years To 20 Years |
Sexes Eligible for Study | Female |
Sampling method | Non-Probability Sample |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria: - Gynecologic cancer patients under chemotherapy. - aged 20 and above. Exclusion Criteria: - Patients who had been enrolled for other investigational drug trials within the data collection period of this study. |
Outcome
Primary Outcome Measures
1. Cancer-related fatigue evaluation by brief fatigue inventory-Taiwanese form(BFI-T) [Change from baseline cancer-related fatigue at each chemotherapy cycle (each cycle is 21 or 28 days)]
Secondary Outcome Measures
1. Quality of life assessments by functional assessment of cancer therapy-general 7 (FACT-G7) [Change from baseline Quality of life at each chemotherapy cycle (each cycle is 21 or 28 days)]
Other Outcome Measures
1. Cytokine and immune markers [Change from baseline cytokine and immune index at each chemotherapy cycle (each cycle is 21 or 28 days)]